Jyong Biotech Ltd. Ordinary Shares

Jyong Biotech Ltd. reaffirmed its strategic focus on pursuing global licensing partnerships for its investigational BPH drug candidate Botreso®. The company highlighted that the global benign prostatic hyperplasia treatment market is estimated at approximately $13 billion in 2025 and is expected to grow to $22 billion to $22.6 billion by 2035, driven by an aging population and a patient population projected to reach 150 million to 156 million by 2035. Current treatments such as alpha-blockers and 5-alpha reductase inhibitors have a five-year discontinuation rate of 60% to 90% due to side effects like dizziness and sexual dysfunction, creating a significant unmet medical need. Jyong Biotech has completed four Phase III clinical trials for Botreso® in Taiwan and the US and continues to engage in discussions with international pharmaceutical companies. The company noted it has already established collaborative relationships and completed its first licensing cooperation agreement.